BRAIN SCIENTIFIC INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 USD | -31.82% |
|
-.--% | -.--% |
| 2023 | Brain Scientific Inc. cancelled the acquisition of IMAC Holdings, Inc.. | CI |
| 2023 | Brain Scientific Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 17.69 | 13.06 | 10.54 |
| Enterprise Value (EV) 1 | 19.09 | 22.93 | 12.66 |
| P/E ratio | -4.12 x | -0.88 x | -0.66 x |
| Yield | - | - | - |
| Capitalization / Revenue | 3,24,93,418 x | 4,91,58,824 x | 4,91,23,725 x |
| EV / Revenue | 3,50,65,162 x | 8,62,82,570 x | 5,89,84,517 x |
| EV / EBITDA | -10.4 x | -2.72 x | -1.44 x |
| EV / FCF | 5.75 x | -37.1 x | -60.7 x |
| FCF Yield | 17.4% | -2.7% | -1.65% |
| Price to Book | -3.68 x | -18.8 x | 2.45 x |
| Nbr of stocks (in thousands) | 231 | 591 | 1,240 |
| Reference price 2 | 76.50 | 22.12 | 8.500 |
| Announcement Date | 15/04/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.0581 | 0.4892 | 0.5443 | 0.2657 | 0.2146 |
| EBITDA 1 | -0.9048 | -1.284 | -0.9689 | -1.832 | -8.437 | -8.784 |
| EBIT 1 | -0.9052 | -1.285 | -0.9702 | -1.833 | -8.656 | -9.608 |
| Operating Margin | - | -2,211.42% | -198.32% | -336.81% | -3,257.41% | -4,478.11% |
| Earnings before Tax (EBT) 1 | -0.9583 | -1.426 | -1.002 | -4.285 | -9.101 | -12.34 |
| Net income 1 | -0.9583 | -1.426 | -1.004 | -4.285 | -9.101 | -12.34 |
| Net margin | - | -2,454.02% | -205.2% | -787.25% | -3,424.57% | -5,753% |
| EPS 2 | -6.655 | -9.720 | -4.436 | -18.56 | -25.21 | -12.95 |
| Free Cash Flow 1 | -0.4913 | -0.7629 | -0.4731 | 3.32 | -0.6181 | -0.2084 |
| FCF margin | - | -1,312.86% | -96.72% | 609.95% | -232.6% | -97.12% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 27/09/18 | 01/04/19 | 31/03/20 | 15/04/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.79 | - | 0.62 | 1.4 | 9.87 | 2.12 |
| Net Cash position 1 | - | 0.11 | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.8779 x | - | -0.6371 x | -0.7641 x | -1.169 x | -0.2409 x |
| Free Cash Flow 1 | -0.49 | -0.76 | -0.47 | 3.32 | -0.62 | -0.21 |
| ROE (net income / shareholders' equity) | 199% | 296% | 211% | 151% | 673% | -682% |
| ROA (Net income/ Total Assets) | -321% | -328% | -257% | -313% | -79.6% | -47.8% |
| Assets 1 | 0.2988 | 0.4351 | 0.39 | 1.367 | 11.44 | 25.82 |
| Book Value Per Share 2 | -0.0600 | -0.2400 | -3.930 | -20.80 | -1.180 | 3.470 |
| Cash Flow per Share 2 | 0.0200 | 0.7200 | 1.150 | 1.180 | 1.330 | 0.6000 |
| Capex 1 | 0 | 0 | 0 | - | 0.06 | 0.03 |
| Capex / Sales | - | 1.97% | 0.21% | - | 22.07% | 15.52% |
| Announcement Date | 27/09/18 | 01/04/19 | 31/03/20 | 15/04/21 | 31/03/22 | 31/03/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 9L | |
| +11.09% | 23TCr | |
| +14.90% | 20TCr | |
| +18.95% | 14TCr | |
| +31.29% | 11TCr | |
| +1.10% | 6.42TCr | |
| +18.52% | 5.41TCr | |
| +5.82% | 5.14TCr | |
| +10.34% | 4.53TCr | |
| +5.25% | 3.73TCr |
- Stock Market
- Equities
- BRSF Stock
- Financials Brain Scientific Inc.
